Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Authors

Jos Bloemers (ORCID: https://orcid.org/0000-0001-5637-7606)
Shaida Khan (ORCID: https://orcid.org/0000-0002-8799-003X)
Puneet Kumar Singh (ORCID: https://orcid.org/0000-0002-4640-8365)
Miriam Freimer (ORCID: https://orcid.org/0000-0001-8282-764X)
Min Kyun Kang (ORCID: https://orcid.org/0000-0002-3843-1645)
James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
Samir Macwan
Urvi Desai (ORCID: https://orcid.org/0000-0002-5169-3201)
Michael D. Weiss (ORCID: https://orcid.org/0000-0003-4064-1032)
Bhupendra Khatri (ORCID: https://orcid.org/0000-0002-1843-5585)
Perry B. Shieh (ORCID: https://orcid.org/0000-0001-7145-7663)
Babak Boroojerdi
Raghav Govindarajan (ORCID: https://orcid.org/0000-0003-0419-9072)
Andreea Lavrov
Todd Levine
Eumorphia Maria Delicha

Institutions

University of North Carolina at Chapel Hill (US)
Eisenhower Medical Center (US)
University of California, Los Angeles (US)
University of California, San Francisco (US)
St. Elizabeth Hospital in Enumclaw (US)
University of Washington Medical Center (US)
St. Elizabeths Hospital (US)
The Ohio State University Wexner Medical Center (US)
St. Elizabeth's Medical Center (US)
Southwestern Medical Center (US)
HonorHealth (US)
UCB Pharma (Germany) (DE)
Southwestern Medical Center (US)
Wake Forest University (US)
UCB Pharma (Belgium) (BE)
The University of Texas Southwestern Medical Center (US)

Publication Details

Journal: Therapeutic Advances in Neurological Disorders
Published: 2025-07-05
DOI: https://doi.org/10.1177/17562864251347283
Citations: 4
Primary Topic: Myasthenia Gravis and Thymoma
Type: article
Field-Weighted Citation Impact: 5.56

Funders

Amgen
Myasthenia Gravis Foundation of America
AstraZeneca
Sanofi
Muscular Dystrophy Association
Biogen
Patient-Centered Outcomes Research Institute
Alexion Pharmaceuticals
F. Hoffmann-La Roche
CSL Behring
Regeneron Pharmaceuticals
Dysimmune Diseases Foundation
TG Therapeutics
Cytokinetics
Argenx
Mitsubishi Tanabe Pharma Corporation
Grifols
National Institutes of Health
Centers for Disease Control and Prevention
EMD Serono

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Jos Bloemers, Shaida Khan, Puneet Kumar Singh, Miriam Freimer et al.

Jul 5, 2025

4 citations

Therapeutic Advances in Neurological Disorders

Myasthenia Gravis and Thymoma

5.56

article

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Jos Bloemers, Shaida Khan, Puneet Kumar Singh, Miriam Freimer, Min Kyun Kang, James F. Howard, Samir Macwan, Urvi Desai, Michael D. Weiss, Bhupendra Khatri, Perry B. Shieh, Babak Boroojerdi, Raghav Govindarajan, Andreea Lavrov, Todd Levine, Eumorphia Maria Delicha

July 5, 2025article en

4 citations

Abstract

No abstract available for this paper.

Therapeutic Advances in Neurological DisordersVol. 18

University of North Carolina at Chapel Hill (US), Eisenhower Medical Center (US), University of California, Los Angeles (US), University of California, San Francisco (US), St. Elizabeth Hospital in Enumclaw (US), University of Washington Medical Center (US), St. Elizabeths Hospital (US), The Ohio State University Wexner Medical Center (US), St. Elizabeth's Medical Center (US), Southwestern Medical Center (US), HonorHealth (US), UCB Pharma (Germany) (DE), Southwestern Medical Center (US), Wake Forest University (US), UCB Pharma (Belgium) (BE), The University of Texas Southwestern Medical Center (US)

Amgen, Myasthenia Gravis Foundation of America, AstraZeneca, Sanofi, Muscular Dystrophy Association, Biogen, Patient-Centered Outcomes Research Institute, Alexion Pharmaceuticals, F. Hoffmann-La Roche, CSL Behring, Regeneron Pharmaceuticals, Dysimmune Diseases Foundation, TG Therapeutics, Cytokinetics, Argenx, Mitsubishi Tanabe Pharma Corporation, Grifols, National Institutes of Health, Centers for Disease Control and Prevention, EMD Serono

Good health and well-being

Openalex Percentile: Top 4%

Myasthenia Gravis and Thymoma

5.56

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.